Stanford Medicine researchers are investigating whether a combination of specific antibodies can reduce early symptoms of COVID-19 in people with mild to moderate cases of the disease. Their effort is part of a multisite clinical trial of an antibody drug developed by Eli Lilly and AbCellera that aims to enroll […]